A Study of BMS-863233 in Patients With Hematologic Cancer
To determine safety, tolerability and maximum tolerated dose of BMS-63233/XL413 in subjects with Refractory Hematologic Cancer
Refractory Hematologic Cancer
DRUG: Cdc7-inhibitor (BMS-863233)|DRUG: Cdc7-inhibitor (BMS-863233)
To determine maximum tolerated dose and anti-tumor activity of BMS-863233/XL413 when administered to subjects with refractory Hematologic Cancer, Every 21 or 28 days until maximum tolerated dose is reached
To determine the safety of BMS-863233/XL413 when administered to subjects with refractory Hematologic Cancer, Every 21 or 28 days until the MTD is reached|To determine the pharmacokinetics of BMS-863233/XL413 when administered to subjects with refractory Hematologic Cancer, Every 21 or 28 days until the MTD is reached|To determine the anti-tumor activity of BMS-863233/XL413 when administered to subjects with refractory Hematologic Cancer, Every 21 or 28 days until the MTD is reached
To determine safety, tolerability and maximum tolerated dose of BMS-63233/XL413 in subjects with Refractory Hematologic Cancer